Relapsed or Refractory Multiple Myeloma Market to Cross $30B as Bispecifics, CAR-T & CELMoDs Reshape Care - Thelansis Reports

Thelansis' market report covers the 8MM (US, EU4, UK, Japan, and China), tracking the shift from later-line rescue therapy to earlier, more personalized intervention in Relapsed or Refractory Multiple Myeloma.

The Relapsed or Refractory Multiple Myeloma (R/R MM) space has moved fast over the last two years, and 2026 looks like another inflection point. Bispecific antibodies are no longer a last resort; they're edging into second-line care. CAR-T is consolidating around fewer, stronger players. And a new class of CELMoDs is lining up behind Revlimid and Pomalyst as those franchises age out. For companies building pipeline strategy, market entry plans, or investment cases in this space, the timing of a fresh, ground-up market view couldn't be better.

That's exactly what this new report delivers: Relapsed or Refractory Multiple Myeloma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036), covering the 8 major markets - the US, Germany, France, Italy, Spain, the UK, Japan, and China.

Request a free sample of Thelansis' Relapsed or Refractory Multiple Myeloma Market Outlook and Forecast Report to secure the complete 2026-2036 forecast, exclusive KOL insights, and competitive pipeline data across the 8 Major Markets: https://thelansis.com/reports/relapsed-or-refractory-multiple-myeloma-market-outlook-forecast-2026-to-2036/

Executive Summary
• The global multiple myeloma market is broadly estimated in the USD 25-31 billion range for 2026, with most forecasts pointing to high single-digit CAGR growth through the mid-2030s as bispecifics, CAR-T, and next-gen oral agents expand the treatment arsenal
• R/R MM remains one of oncology's most active battlegrounds, patients cycle through multiple lines of therapy, and each relapse opens a fresh commercial window for newer mechanisms
• The report maps epidemiology, current standard of care, emerging pipeline, and 10-year forecasts across the 8MM, including a dedicated view on China, where diagnosis rates and drug access are evolving quickly
• It's built for market access teams, BD&L, competitive intelligence, and investment groups who need a defensible, up-to-date view of where this market is headed.

Key Emerging Players
• Johnson & Johnson (Janssen) - continues to lead with TECVAYLI (teclistamab) and TALVEY (talquetamab), and recently expanded teclistamab into combination use with daratumumab as an earlier-line option
• Pfizer - ELREXFIO (elranatamab) remains a core bispecific competitor, with real-world uptake data now maturing
• Regeneron - Lynozyfic (linvoseltamab) entered the market as the newest BCMA-directed bispecific, with several follow-on registrational trials underway
• Legend Biotech / J&J and Bristol Myers Squibb - CARVYKTI and ABECMA continue to anchor the CAR-T segment, though manufacturing capacity and access remain competitive differentiators
• Bristol Myers Squibb - advancing iberdomide, a next-generation CELMoD positioned as a successor to its IMiD franchise as Revlimid and Pomalyst face generic pressure
• Gilead / Arcellx - Gilead's move to acquire Arcellx signals continued consolidation and fresh capital flowing into cell therapy for myeloma
• A wave of trispecific antibodies and combination regimens are also advancing through earlier trial stages, adding to a genuinely crowded pipeline

Request a sample report for an in-depth analysis of key emerging players, pipeline staging, and mechanisms of action in Relapsed or Refractory Multiple Myeloma: https://thelansis.com/reports/relapsed-or-refractory-multiple-myeloma-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rrmm_mo

Key Current Therapies or Standard of Care
• Proteasome inhibitors (bortezomib, carfilzomib) and IMiDs (lenalidomide, pomalidomide) still anchor most regimens, typically alongside anti-CD38 antibodies like daratumumab
• BCMA and GPRC5D-directed bispecific antibodies have moved from later-line salvage therapy toward second-line use, a genuine shift in how physicians sequence treatment
• CAR-T therapies remain reserved for eligible, heavily pretreated patients, constrained by manufacturing timelines and infrastructure needs
• Triple-class refractory disease: resistant to a PI, an IMiD, and an anti-CD38 antibody, is still the toughest population to treat, and the one drawing the most R&D attention

Key Market Drivers/Trends
• Off-the-shelf bispecifics are displacing some CAR-T demand simply because they don't require leukapheresis or lengthy manufacturing lead times
• Regulatory pathways are moving faster, several bispecifics and CAR-T constructs have gone from filing to approval in under a year
• An aging global population is pushing case counts higher even where age-adjusted incidence is flat, particularly across Japan and China
• China's diagnostic infrastructure and reimbursement pathways are improving, making it an increasingly important growth market within the 8MM
• M&A activity (Gilead-Arcellx being the latest example) points to continued consolidation and fresh investment in cell and immune-based therapies
• CELMoDs are emerging as the next wave of oral, at-home treatment options as the current IMiD generation nears the end of its commercial life

Translate these macro drivers into a competitive advantage. Request the Thelansis Relapsed or Refractory Multiple Myeloma sample report to unlock granular pipeline analysis, deal tracking, and market forecasts: https://thelansis.com/reports/relapsed-or-refractory-multiple-myeloma-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rrmm_mo

Key Unmet Need & KOL Expectations
• Physicians consistently flag triple-class and penta-refractory disease as the segment with the least effective options and the worst outcomes
• There's a real appetite for regimens that reduce cytokine release syndrome and infection risk - safety, not just efficacy, is becoming the differentiator as response rates converge across bispecifics
• KOLs are watching closely for randomized, head-to-head data comparing bispecifics and CAR-T to established standards of care, rather than relying on single-arm trial results
• Sequencing strategy which therapy to use first, and what to hold in reserve, is becoming a genuine clinical dilemma as more options reach the same treatment line

Commercial Opportunity
• Earlier-line expansion for bispecifics represents one of the largest near-term revenue opportunities in the R/R MM space
• CELMoDs offer a lower-infrastructure, higher-volume commercial model compared to cell therapies, attractive for markets with limited specialized treatment centers
• China and other expanding-access markets within the 8MM offer meaningful volume upside as diagnosis and reimbursement continue to improve
• Companies with differentiated safety profiles, simpler administration, or combination strategies are best positioned to capture share as the market matures past first-generation bispecifics

Access the complete Relapsed or Refractory Multiple Myeloma market outlook and forecast report to explore the evolving market and future commercial opportunities: https://thelansis.com/reports/relapsed-or-refractory-multiple-myeloma-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rrmm_mo

This report is intended for pharmaceutical and biotech strategy teams, market access professionals, investors, and consultants seeking a data-driven view of the Relapsed or Refractory Multiple Myeloma treatment landscape through 2036.

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.